View the current JRNYS program details (official JRNYS page) Disclaimers Content and Medical Disclaimer: This article is an advertorial produced for informational purposes only
During the initial 12-week phase, you use one vial per weekly session (12 vials total)
The starting dose (0.25 mg semaglutide or 2.5 mg tirzepatide) is a titration dose, not a therapeutic dose
Growth Factor Gene Expression Growth factor gene expression increases substantially across multiple pathways: VEGF (Vascular Endothelial Growth Factor) Shows dose-dependent increases in mesenchymal stem cells, promoting angiogenesis and blood vessel formation bFGF (Basic Fibroblast Growth Factor) Increases 230% when combined with LED irradiation at 625-635 nm wavelengths BDNF (Brain-Derived Neurotrophic Factor) Receives stimulation for nerve outgrowth and neurological support ANGPT1 (Angiopoietin 1) Increases 487% for vascular stabilization BMP-2 (Bone Morphogenetic Protein 2) Receives upregulation for bone tissue regeneration Inflammatory Pathway Suppression Inflammatory pathway suppression occurs through multiple mechanisms
(Buhler) [5] Sources and Research References [1] Arla Foods Ingredients targets GLP-1 companion nutrition at Vitafoods Europe, 2026 [2] MyNetDiary Launches GLP-1 Companion for Ozempic, Wegovy, and Mounjaro Users, 2026 [3] HTBA to launch Leanara GLP-1 companion ingredient at Vitafoods Europe 2026, 2026 [4] Amazon launches GLP-1 weight loss program, promising fast, convenient access, 2026 [5] Brightseed Launches BioMetaControl, a Nature-Inspired GLP-1 Companion for Metabolic Health., 2025 GLP-1 Companion Products Market Definition The GLP-1 companion products market is made up of a variety of complementary products and services aimed at improving the efficacy, safety, and overall success of GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro
This four-day series presents a blend of interventions, including IV therapies, participants can tailor to suit their preferences
